schizophrenia

News

Neurocrine slides as schizophrenia data disappoints

Shares in Neurocrine Bioscience took a tumble after the company reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors.

News

Neurosterix emerges with $63m for neuroscience pipeline

A brand new biotech – Neurosterix – has been formed to take forward neuroscience programmes that originated at Switzerland’s Addex Therapeutics, including a drug for schiz

News

BMS completes $14bn takeover of Karuna

Bristol-Myers Squibb has got its $14 billion acquisition of Karuna Therapeutics over the line, having had to withdraw and refile antitrust paperwork and contend with a sha

News

Steve Davis, president and chief executive of Acadia Pharma

Acadia pulls trials of pimavanserin after schizophrenia fail

Acadia Pharma’s plan to develop pimavanserin as a treatment for additional indications is in disarray after the drug failed a phase 3 trial in schizophrenia.

News

Boehringer licenses Sosei schizophrenia drugs in €755m deal

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activit

News

Minerva slumps as FDA finds fault with schizophrenia filing

Shares in Minerva Neurosciences have lost more than half their value after the FDA rejected its marketing application for roluperidone as a treatment for the negative symp

Neurocrine slides as schizophrenia data disappoints

Neurosterix emerges with $63m for neuroscience pipeline

BMS completes $14bn takeover of Karuna

Acadia pulls trials of pimavanserin after schizophrenia fail

Boehringer licenses Sosei schizophrenia drugs in €755m deal

Minerva slumps as FDA finds fault with schizophrenia filing

Agios mulls early FDA filing for sickle cell therapy

Using AI-driven synthetic personas to take your insights fur...

schizophrenia

Editor's Picks